Tag: Acoramidis

In a significant development for patients with a specific type of amyloidosis, recent FDA approvals have provided new and transformative options for treatment. This includes new drugs to treat amyloidosis, specifically targeting transthyretin-mediated cardiac amyloidosis (ATTR-CM) with different mechanisms of action.

An estimated 4,000 people develop primary amyloidosis in the U.S. each year, a rare disease that has seen a recent surge in treatment options [1.10.3]. So, what is the new drug for amyloidosis? The answer depends on the type, with several groundbreaking therapies approved in late 2023 and 2024 [1.3.1, 1.4.1].

In November 2024, the U.S. Food and Drug Administration (FDA) approved Attruby (acoramidis) to treat adults with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM). This oral medication serves a crucial role in reducing death and hospitalizations related to heart problems caused by this rare and serious condition. If you're asking, **'What is Attruby for?'**, this guide will explain its purpose, function, and other important information for patients.